TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8930424

Group type: EXPERIMENTAL
Intervention: valsartan 20 mg
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: valsartan 320 mg
Number of subjects: 736

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 736
Study: 8332965

Group type: EXPERIMENTAL
Intervention: Ticlopidine (2 x 250 mg daily) from the second preoperative day until the seventh postoperative day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo until the day of surgery and further acenocoumarol post-operatively
Number of subjects: 46
Study: 3771472

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg + Isoproterenol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg + Isoproterenol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg + Isoproterenol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg + Isoproterenol
Number of subjects: 18
Study: 29506504

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 28.8 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 14.4 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 7.2 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 3.6 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium MDI 34 μg
Number of subjects: 0
Study: 27255474

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5mg daily for 12 months)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (non-supplemented)
Number of subjects: 355
Study: 25022762

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whole blood injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dry needle tendon fenestration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham injection with physical therapy alone
Number of subjects: 100
Study: 22886853

Group type: EXPERIMENTAL
Intervention: Low demand, high basal infusion (LDHI) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: High demand, low basal infusion (HDLI) strategy
Number of subjects: 0
Study: 20619073

Group type: EXPERIMENTAL
Intervention: log-transformed sum of triceps, biceps, subscapular and supra-iliac skinfolds (logSF4)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: log-transformed sum of triceps and subscapular skinfolds (logSF2)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: log-transformed triceps skinfold (logTSF)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: log-transformed triceps skinfold (logTSF) combined with waist circumference
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: BMI combined with waist circumference
Number of subjects: 372
Study: 18218746

Group type: EXPERIMENTAL
Intervention: Stroking on the ventral part of the neck
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stroking on the withers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stroking on the lateral side of the chest
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple human presence (control)
Number of subjects: 60
Study: 16167447

Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study: 12664016

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10802492

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) 20 ppm
Number of subjects: 235

Group type: COMPARATOR
Intervention: 100% oxygen (control)
Number of subjects: 235
Study: 9252000

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulative physiotherapy treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 1504055

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) administered as a 1- or 2-hour i.v. infusion, with doses of 12 x 10(6) IU/m2, 18 x 10(6) IU/m2, and 24 x 10(6) IU/m2, given every Monday/Wednesday/Friday for 3 weeks
Number of subjects: 11
Study: 6320226

Group type: EXPERIMENTAL
Intervention: delta 9‐tetrahydrocannabinol (THC) 17.5 mg orally
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nabilone 2 mg orally
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1-g marihuana cigarette containing 1.83% THC, smoked
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 23
Study: 31509674

Group type: EXPERIMENTAL
Intervention: n-3 group (fish-oil capsules containing 900 mg of n-3 long-chain polyunsaturated fatty acids)
Number of subjects: 5517

Group type: COMPARATOR
Intervention: Control group (vegetable-oil capsules containing trace n-3 long-chain polyunsaturated fatty acids)
Number of subjects: 5517

Group type: EXPERIMENTAL
Intervention: n-3 group
Number of subjects: 5517
Study: 29038282

Group type: EXPERIMENTAL
Intervention: 33% daily dosing under directly observed therapy (DOT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 67% daily dosing under directly observed therapy (DOT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100% daily dosing under directly observed therapy (DOT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All dosing regimens
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of TFV-DP levels between sexes
Number of subjects: 48
Study: 27519769

Group type: EXPERIMENTAL
Intervention: Telmisartan (20 mg/day) for 12 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Telmisartan (30 mg/kg/day, orally) for 7 days
Number of subjects: 15
Study: 23455576

Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: ART restorations using high-viscosity glass ionomer
Number of subjects: 258
Study: 23238507

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol infusion 1-3 mg per hour
Number of subjects: 165

Group type: COMPARATOR
Intervention: Biatrial pacing and oral metoprolol (50-150 mg daily for 72 hours)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol infusion
Number of subjects: 165

Group type: COMPARATOR
Intervention: Biatrial pacing and oral metoprolol
Number of subjects: 165
Study: 20489805

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18721511

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 640

Group type: COMPARATOR
Intervention: Moderate statin therapy
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Patients with previous CABG
Number of subjects: 640
Study: 15793459

Group type: EXPERIMENTAL
Intervention: Glycolic acid application (initially at home for 2 weeks, followed by higher concentration in-office weekly for six applications)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multivitamin product (topical application at home daily for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cream base (placebo) for 3 months
Number of subjects: 30
Study: 12356207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 10624760

Group type: EXPERIMENTAL
Intervention: Maximal incremental cycle ergometer test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Breathing frequency
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tidal volume
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: End-tidal partial pressure of carbon dioxide (PET,CO2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Relationship between PET,CO2 and respiratory frequency during recovery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Respiratory complaints and paresthesias
Number of subjects: 24
Study: 7547654

Group type: EXPERIMENTAL
Intervention: 10 micrograms epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 micrograms epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine plain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine with 10 micrograms epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine with 15 micrograms epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 30
Study: 1781798

Group type: EXPERIMENTAL
Intervention: Gallopamil (0.02 mg/kg/h followed by 0.03 mg/kg/h after 24 hours)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 15
Study: 6589735

Group type: EXPERIMENTAL
Intervention: Interdental brushes
Number of subjects: 9

Group type: COMPARATOR
Intervention: Waxed dental floss
Number of subjects: 9
Study: 31318613

Group type: EXPERIMENTAL
Intervention: Calf raises every 10 min during 3 h of sitting (CALF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with no calf raises during 3 h of sitting (CON)
Number of subjects: 20
Study: 28220291

Group type: EXPERIMENTAL
Intervention: Gufoni maneuver (n = 70)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Mastoid oscillation (n = 67)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Sham maneuver (n = 72)
Number of subjects: 209
Study: 26166528

Group type: EXPERIMENTAL
Intervention: Mandibular protrusion of Class III
Number of subjects: 180

Group type: COMPARATOR
Intervention: Maxillary retrusion of Class III
Number of subjects: 180

Group type: COMPARATOR
Intervention: Class I
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mandibular retrusion of Class III
Number of subjects: 180
Study: 25119953

Group type: EXPERIMENTAL
Intervention: Health Literacy prototype
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Drug Facts
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Column
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Current standard Med Guides
Number of subjects: 1003
Study: 22080629

Group type: EXPERIMENTAL
Intervention: Continuous chest compression cardiopulmonary resuscitation
Number of subjects: 406

Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation
Number of subjects: 406
Study: 19359178

Group type: EXPERIMENTAL
Intervention: Standard shoes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soft sole shoes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-collar shoes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Wet surface
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Older subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Young subjects
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control surface
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Irregular surface
Number of subjects: 36
Study: 17530961

Group type: EXPERIMENTAL
Intervention: 1 linear position transducer (1‐LPT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 linear position transducers and a force plate (2‐LPT + FP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 linear position transducer and a force plate (1‐LPT + FP)
Number of subjects: 9
Study: 15329504

Group type: EXPERIMENTAL
Intervention: Bepridil alone or in combination with aprindine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Electrical conversion with conventional antiarrhythmic drugs other than bepridil and aprindine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bepridil treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Electrical conversion
Number of subjects: 38
Study: 11601567

Group type: EXPERIMENTAL
Intervention: AND-HB (300 mg androstenediol, 480 mg saw palmetto, 450 mg indole-3-carbinol, 300 mg chrysin, 1500 mg gamma-linolenic acid, 1350 mg Tribulus terrestris per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: AND-HB
Number of subjects: 55
Study: 9685822

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg, twice daily for a week)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (twice daily for a week)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8027274

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) co-treatment with human menopausal gonadotrophins (HMG) and human chorionic gonadotrophin (HCG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: HMG/HCG alone
Number of subjects: 32
Study: 2681819

Group type: EXPERIMENTAL
Intervention: Verbal and visual feedback system
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 22
Study: 797678

Group type: EXPERIMENTAL
Intervention: Prophylactic central nervous system (CNS) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: No prophylactic CNS therapy (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prophylactic CNS therapy
Number of subjects: 50
Study: 29984550

Group type: EXPERIMENTAL
Intervention: ERP + CT
Number of subjects: 127

Group type: COMPARATOR
Intervention: ERP
Number of subjects: 127
Study: 29029616

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention guided by peer-trainers
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 72
Study: 25940329

Group type: EXPERIMENTAL
Intervention: 5% glucose in water solution (group G5W)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 3.33% glucose in 0.3% NaCl (group GNaCl)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ringer's acetate (group RA)
Number of subjects: 91
Study: 23044342

Group type: EXPERIMENTAL
Intervention: Puerarin (PUE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 0
Study: 22068140

Group type: EXPERIMENTAL
Intervention: Urgotul Trio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepilex Border
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allevyn Adhesive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Versiva XC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comfeel Plus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biatain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 0
Study: 19968380

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with more than 9 sessions
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with problem-solving treatment component
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with social skills treatment component
Number of subjects: 334
Study: 17699181

Group type: EXPERIMENTAL
Intervention: Percutaneous carotid stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical carotid endarterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factor management
Number of subjects: 0
Study: 15447898

Group type: EXPERIMENTAL
Intervention: 200 microg folic acid in a tablet
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 200 microg natural folate provided as spinach
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 200 microg natural folate provided as yeast
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 96
Study: 11489002

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gemcitabine-paclitaxel
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (first-line treatment)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gemcitabine, paclitaxel, and cisplatin or carboplatin (triplet therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gemcitabine, paclitaxel, and carboplatin (combination treatment)
Number of subjects: 25
Study: 9541344

Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl (P + F)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Midazolam and fentanyl (M + F)
Number of subjects: 57
Study: 7999652

Group type: EXPERIMENTAL
Intervention: Interscalene block
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Axillary block
Number of subjects: 508

Group type: COMPARATOR
Intervention: Transarterial approach for axillary block
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 508
Study: 3421208

Group type: EXPERIMENTAL
Intervention: 5-100 g linseed oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: linolenic acid absorption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mouth-to-ileum transit time
Number of subjects: 0
Study: 29326318

Group type: EXPERIMENTAL
Intervention: ELTGOL technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo exercises
Number of subjects: 44
Study: 27914501

Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan (0.2 μg kg‐1 min‐1 for the first hour followed by 0.1 μg/kg for 23 hours)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 880
Study: 24180327

Group type: EXPERIMENTAL
Intervention: Enhanced calibration of CGM device (calibrated at variable intervals of 1-6 hours using ABG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard calibration of CGM device (calibrated according to manufacturer's instructions at 1, 2, 10, and 24 hours)
Number of subjects: 24
Study: 22013887

Group type: EXPERIMENTAL
Intervention: Dual-wave insulin boluses for pizza dinner (45g carbohydrates, 400kcal from fat-protein)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group using standard insulin dose calculation (n Carbohydrate Units×ICR)
Number of subjects: 24
Study: 20711065

Group type: EXPERIMENTAL
Intervention: Early physical and occupational therapy (daily sedative interruption followed by therapy every hospital day)
Number of subjects: 49
Study: 19145732

Group type: EXPERIMENTAL
Intervention: Soft diet
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clear liquid diet
Number of subjects: 101
Study: 16351775

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup (20 mg elemental Fe twice daily) + single dose of vitamin A (33,000 microg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo + single dose of vitamin A (33,000 microg)
Number of subjects: 169
Study: 12438295

Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 2096

Group type: COMPARATOR
Intervention: no beta-blockers
Number of subjects: 2096
Study: 10876850

Group type: EXPERIMENTAL
Intervention: Concentrated inactivated tissue-culture tick-borne encephalitis vaccine
Number of subjects: 0
Study: 8607736

Group type: EXPERIMENTAL
Intervention: EMG biofeedback treatment (one 45-minute session)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Additional biofeedback treatment sessions (average of 3 sessions)
Number of subjects: 100
Study: 2013954

Group type: EXPERIMENTAL
Intervention: Center-based care (2 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study: 7322958

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study: 31977638

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 20
Study: 31088522

Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 7 hours)
Number of subjects: 62517

Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 7 hours) for boys (6-12 years and 13-17 years)
Number of subjects: 62517

Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 7 hours) for older girls (13-17 years)
Number of subjects: 62517
Study: 28070957

Group type: EXPERIMENTAL
Intervention: Hartmann's solution (HS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 77
Study: 25592188

Group type: EXPERIMENTAL
Intervention: Low-intensity WBV (peak acceleration=0.96g)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-intensity WBV (peak acceleration=1.61g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no WBV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-intensity WBV
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-intensity WBV
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-intensity WBV and High-intensity WBV
Number of subjects: 48
Study: 25627184

Group type: EXPERIMENTAL
Intervention: Aspheric intraocular lens (Akreos AO)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spherical intraocular lens (Akreos Fit)
Number of subjects: 25
Study: 21075062

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP™) - 112mg via Novartis T‐326 Inhaler
Number of subjects: 553

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS, TOBI®) - 300mg/5mL via PARI LC® PLUS nebulizer
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP™)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS, TOBI®)
Number of subjects: 553
Study: 19887042

Group type: EXPERIMENTAL
Intervention: GrHu group (multisensory training approach)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GrCl group (classical rehabilitation protocol)
Number of subjects: 40
Study: 18246982

Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 15724223

Group type: EXPERIMENTAL
Intervention: Disease Management Programme (DMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12468450

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (immunosuppressive drug) paired with a distinctively flavored drink (conditioned stimulus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules paired with the conditioned stimulus (drink)
Number of subjects: 0